ANL 28.17 Decreased By ▼ -0.63 (-2.19%)
ASC 16.76 Increased By ▲ 0.28 (1.7%)
ASL 23.95 Increased By ▲ 0.46 (1.96%)
AVN 91.66 Decreased By ▼ -0.16 (-0.17%)
BOP 9.71 Decreased By ▼ -0.11 (-1.12%)
BYCO 9.93 Decreased By ▼ -0.28 (-2.74%)
DGKC 113.50 Decreased By ▼ -0.70 (-0.61%)
EPCL 48.84 Decreased By ▼ -0.77 (-1.55%)
FCCL 21.66 Increased By ▲ 0.31 (1.45%)
FFBL 27.70 Increased By ▲ 1.21 (4.57%)
FFL 17.99 Decreased By ▼ -0.30 (-1.64%)
HASCOL 14.82 Decreased By ▼ -0.16 (-1.07%)
HUBC 86.45 Increased By ▲ 1.05 (1.23%)
HUMNL 7.35 Increased By ▲ 0.02 (0.27%)
JSCL 29.60 Decreased By ▼ -0.25 (-0.84%)
KAPCO 38.31 Decreased By ▼ -0.19 (-0.49%)
KEL 4.24 Decreased By ▼ -0.06 (-1.4%)
LOTCHEM 15.96 Decreased By ▼ -0.27 (-1.66%)
MLCF 43.55 Decreased By ▼ -0.52 (-1.18%)
PAEL 40.60 Decreased By ▼ -0.50 (-1.22%)
PIBTL 13.00 Decreased By ▼ -0.12 (-0.91%)
POWER 11.78 Increased By ▲ 0.67 (6.03%)
PPL 97.45 Decreased By ▼ -0.65 (-0.66%)
PRL 25.48 Decreased By ▼ -0.32 (-1.24%)
PTC 9.78 Decreased By ▼ -0.13 (-1.31%)
SILK 1.21 Decreased By ▼ -0.02 (-1.63%)
SNGP 46.49 Decreased By ▼ -0.30 (-0.64%)
TRG 97.38 Increased By ▲ 2.18 (2.29%)
UNITY 31.58 Decreased By ▼ -0.62 (-1.93%)
WTL 1.18 No Change ▼ 0.00 (0%)
BR100 4,856 Decreased By ▼ -11.74 (-0.24%)
BR30 24,507 Decreased By ▼ -1.43 (-0.01%)
KSE100 45,931 Decreased By ▼ -58.35 (-0.13%)
KSE30 19,110 Decreased By ▼ -68.04 (-0.35%)
Business & Finance

Indian drugmaker Biological E. starts human trials of COVID-19 vaccine candidate

  • The trial will test two doses of the vaccine in about 360 healthy subjects aged 18 to 65 years, Biological E. said.
  • India has reported 8.85 million confirmed cases of the virus - the second highest in the world,
16 Nov 2020

BENGALURU: India's Biological E. Ltd has started human trials of its COVID-19 vaccine candidate and expects results by February, the drugmaker said on Monday.

The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate - being developed with Baylor College of Medicine in Houston, Texas, and US-based Dynavax Technologies Corp - after getting the green signal from the Drugs Controller General of India.

The trial will test two doses of the vaccine in about 360 healthy subjects aged 18 to 65 years, Biological E. said.

Separately, Bharat Biotech, a private company developing a vaccine candidate, COVAXIN, with the government-run Indian Council of Medical Research, said it was starting phase III trials on Monday.

India has reported 8.85 million confirmed cases of the virus - the second highest in the world, after the United States - but the number of new daily cases has fallen since a peak in mid-September.

Meanwhile, hopes for a vaccine got a fresh boost after US-based Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial.

Last week, drugmaker Pfizer Inc and German partner BioNTech SE said their vaccine was more than 90% effective.

An Indian government-backed vaccine could be launched as early as February - months earlier than expected - as last-stage trials begin this month, a senior government scientist previously told Reuters.